Interview with Dr. Peter Traber, CEO of Galectin Therapeutics
Sully and Russ T Nailz interview Galectin Therapeutics CEO, Dr. Peter Traber. Dr. Traber discusses the very real progress that GALT is making with respect to liver diseases worldwide.
Galectin Therapeutics is a biotechnology company focused on discovery and development. GALT applies their leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer.